Actively Recruiting
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Led by JIANYANG WANG · Updated on 2025-07-09
44
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with negative epidermal growth factor receptor (EGFR)-mutated unresectable locally advanced non-small cell lung cancer (LA-NSCLC). However, parts of patients only receive sequential chemoradiotherapy (sCRT) due to various reasons. This phase II study aimed to improve the outcomes of patients receiving sCRT by combining anti-angiogenesis therapy (Anlotinib) during radiotherapy course.We hypothesize that the combination of radiotherapy with anlotinib could improve the 2-year PFS rate from 35% with sCRT to 50. The accrual target was 44 patients.
CONDITIONS
Official Title
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older with any sex
- Histologically or cytologically confirmed locally advanced unresectable NSCLC with negative EGFR or ALK/ROS1 mutations
- Peripheral tumor, or central lung cancer with non-squamous or mixed tissue with less than 50% squamous carcinoma
- Eastern Cooperative Oncology Group (ECOG) performance score 2 or less
- Received systemic chemotherapy or combined chemotherapy and immunotherapy for at least 4 weeks without progression
- No tumor cavity and located at least 1 cm away from the main pulmonary artery trunk
- No symptoms of hemoptysis
- Adequate liver and kidney function with negative urine protein
- Expected survival longer than 6 months
You will not qualify if you...
- Receiving treatment for other cancers except curable non-melanoma skin cancer or cervical carcinoma in situ
- Previous cancer within the past 5 years
- History of thoracic radiotherapy, hemoptysis, heart attack, or stroke within the past 3 months
- Uncontrolled or active lung inflammation
- Participation in other clinical trials
- Pregnant women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Radiation Oncology,Cancer Institute and Hospital,Chinese
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
Research Team
J
jianyang wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here